---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-032613"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:18:14.599569+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q3 net loss $12.7M; appoints Dr. Kenigsberg as CMO for Electrophysiology

## Summary
- GAAP net loss $12.7M in Q3 2024 vs $10.6M in Q3 2023; cash $79M including $60M rights offering.
- Placed nsPFA Percutaneous Electrode System at 7 US pilot sites; pivotal trial for thyroid nodules expected mid-2025.
- Over 50 patients treated with nano-PFA 360 catheter in European feasibility study; two additional study sites engaged.
- Appointed Dr. David Kenigsberg as CMO of Electrophysiology; added Dr. Andrea Natale as medical advisor.
- Cash burn $8.5M in Q3; warrants could raise up to $66M at $11/share, exercisable immediately.

## SEC filing metadata
- accession: 0001437749-24-032613
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774924032613/0001437749-24-032613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774924032613/plse20241028_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-032613
- JSON: https://secwatch.observer/filing/0001437749-24-032613.json
- Plain text: https://secwatch.observer/filing/0001437749-24-032613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.